G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept

被引:66
作者
Deotare, U. [1 ]
Al-Dawsari, G. [1 ]
Couban, S. [2 ]
Lipton, J. H. [1 ]
机构
[1] Univ Toronto, Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Allogene Bone Marrow Transplant Program, Toronto, ON M5G 2M9, Canada
[2] Dalhousie Univ, Dept Med, Halifax, NS, Canada
关键词
COLONY-STIMULATING FACTOR; VERSUS-HOST-DISEASE; QUALITY-OF-LIFE; TERM-FOLLOW-UP; PERIPHERAL-BLOOD; RANDOMIZED-TRIAL; PROGENITOR CELLS; HEALTHY DONORS; INCREASED RISK; EUROPEAN-GROUP;
D O I
10.1038/bmt.2015.80
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The source of hematopoietic stem cells (HSCs) for allogeneic transplantation has evolved over the last decades, from the sole use of unstimulated bone marrow (BM) to the use of G-CSF (filgrastim)-mobilized peripheral blood, G-CSF-primed BM (G-BM) and cord blood. G-CSF-mobilized PBSC has replaced BM as the most commonly used source of allogeneic stem cells. G-BM is a source of HSCs, with studies demonstrating the safety and feasibility of this strategy with the potential for reducing GvHD, while retaining the speed of engraftment. Although the G-BM had lost its use as the optimal source of stem cells, after the widespread use of haploidentical transplantation, their use has resurfaced in 2010. This source can still be used in today's world of transplantation in aplastic anemia and other benign diseases, as well as in children donors. This study intends to review the evidence for this approach and whether this approach still has merit in the ever-evolving field of allogenic HSC transplantation. The merit of G-BM is its ability to offer speed of engraftment with reduced GvHD.
引用
收藏
页码:1150 / 1156
页数:7
相关论文
共 68 条
[1]   Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta-analysis of nine randomized trials [J].
al-Jurf, M ;
Aranha, F ;
Annassetti, C ;
Apperley, JF ;
Baynes, R ;
Bensinger, WI ;
Blaise, D ;
Chaudhary, MA ;
Clarke, M ;
Cornelissen, JJ ;
Couban, S ;
Cutler, C ;
Djulbegovic, B ;
Gyger, M ;
Gratwohl, A ;
Heldal, D ;
Van der Holt, B ;
Hozo, I ;
Kuentz, M ;
Kumar, A ;
Lipton, J ;
Matchamm, J ;
Mohty, M ;
Morton, J ;
Panzarella, T ;
Powles, R ;
Richards, SM ;
Sahovic, E ;
Schmitz, N ;
Simpson, DR ;
Sirohi, B ;
Soares, HP ;
de Souza, CA ;
Vigorito, AC ;
Wheatley, K .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5074-5087
[2]  
Anderlini P, 1997, BLOOD, V90, P903
[3]   Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project [J].
Bennett, Charles L. ;
Evens, Andrew M. ;
Andritsos, Leslie A. ;
Balasubramanian, Lakshmi ;
Mai, Mark ;
Fisher, Matthew J. ;
Kuzel, Timothy M. ;
Angelotta, Cara ;
Mckoy, June M. ;
Vose, Julie M. ;
Bierman, Philip J. ;
Kuter, David J. ;
Trifilio, Steven M. ;
Devine, Steven M. ;
Tallman, Martin S. .
BRITISH JOURNAL OF HAEMATOLOGY, 2006, 135 (05) :642-650
[4]   Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. [J].
Bensinger, WI ;
Martin, PJ ;
Storer, B ;
Clift, R ;
Forman, SJ ;
Negrin, R ;
Kashyap, A ;
Flowers, MED ;
Lilleby, K ;
Chauncey, TR ;
Storb, R ;
Appelbaum, FR ;
Rowley, S ;
Heimfeld, S ;
Blume, K .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (03) :175-181
[5]   COLLECTION OF CIRCULATING HEMATOPOIETIC-CELLS AFTER CHEMOTHERAPY IN ACUTE NON-LYMPHOCYTIC LEUKEMIA [J].
BERNARD, P ;
REIFFERS, J ;
VEZON, G ;
SARRAT, A ;
MARIT, G ;
DAVID, B ;
BROUSTET, A .
BRITISH JOURNAL OF HAEMATOLOGY, 1985, 61 (03) :577-578
[6]   Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors [J].
Billen, Annelies ;
Madrigal, J. Alejandro ;
Strydom, Andre ;
Szydlo, Richard M. ;
Switzer, Galen E. ;
Shaw, Bronwen E. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) :350-356
[7]  
BORTIN MM, 1983, EXP HEMATOL, V11, P916
[8]   An evaluation of the donor experience in the Canadian multicenter randomized trial of bone marrow versus peripheral blood allografting [J].
Bredeson, C ;
Leger, C ;
Couban, S ;
Simpson, D ;
Huebsch, L ;
Walker, I ;
Shore, T ;
Howson-Jan, K ;
Panzarella, T ;
Messner, H ;
Barnett, M ;
Lipton, C .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (06) :405-414
[9]  
BUCKNER CD, 1984, BLOOD, V64, P630
[10]   Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor [J].
Cavallaro, AM ;
Lilleby, K ;
Majolino, I ;
Storb, R ;
Appelbaum, FR ;
Rowley, SD ;
Bensinger, WI .
BONE MARROW TRANSPLANTATION, 2000, 25 (01) :85-89